[1] |
Ferrari D, Codecà C, Fiore J , et al. Biomolecular markers in cancer of the tongue[J]. J Oncol, 2009,2009:412908.
|
[2] |
Jing Y, Jin Y, Wang YJ , et al. SPARC promotes the proliferation and metastasis of oral squamous cell carcinoma by PI3K/AKT/PDGFB/PDGFRβ axis[J]. J Cell Physiol, 2019,234(9):15581-15593.
|
[3] |
Khan AH, Prakash A, Kumar D , et al. Virtual screening and pharmacophore studies for ftase inhibitors using Indian plant anticancer compounds database[J]. Bioinformation, 2010,5(2):62-66.
|
[4] |
Wang JY, Yao X, Huang J . New tricks for human farnesyltransferase inhibitor: cancer and beyond[J]. Medchemcomm, 2017,8(5):841-854.
|
[5] |
Hancock JF, Parton RG . Ras plasma membrane signalling platforms[J]. Biochem J, 2005,389(Pt 1):1-11.
|
[6] |
Cox AD, der CJ, Philips MR . Targeting RAS membrane association: back to the future for anti-RAS drug discovery[J]. Clin Cancer Res, 2015,21(8):1819-1827.
|
[7] |
Lurje G, Lenz HJ . EGFR signaling and drug discovery[J]. Oncology, 2009,77(6):400-410.
|
[8] |
Karnoub AE, Weinberg RA . Ras oncogenes: split personalities[J]. Nat Rev Mol Cell Biol, 2008,9(7):517-531.
|
[9] |
夏炎枝, 红凌 . 蛋白质异戊烯化修饰与抗肿瘤研究[J]. 医学分子生物学杂志, 2010,7(5):435-440.
|
|
Xia YZ, Hong L . Protein prenylation and anti-cancer research[J]. J Med Mol Biol, 2010,7(5):435-440.
|
[10] |
Malumbres M, Barbacid M . RAS oncogenes: the first 30 years[J]. Nat Rev Cancer, 2003,3(6):459-465.
|
[11] |
Simanshu DK, Nissley DV, McCormick F . RAS proteins and their regulators in human disease[J]. Cell, 2017,170(1):17-33.
|
[12] |
Murugan AK, Munirajan AK, Tsuchida N . Ras oncogenes in oral cancer: the past 20 years[J]. Oral Oncol, 2012,48(5):383-392.
|
[13] |
Vasan N, Boyer JL, Herbst RS . A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer[J]. Clin Cancer Res, 2014,20(15):3921-3930.
|
[14] |
Cox AD, Fesik SW, Kimmelman AC , et al. Drugging the undruggable RAS: mission possible[J]. Nat Rev Drug Discov, 2014,13(11):828-851.
|
[15] |
Jo H, Zhang R, Zhang H , et al. NF-κB is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis[J]. Oncogene, 2000,19(7):841-849.
|
[16] |
Yang JM, Splittgerber R, Yull FE , et al. Conditional ablation of Ikkb inhibits melanoma tumor development in mice[J]. J Clin Invest, 2010,120(7):2563-2574.
|
[17] |
Aggarwal BB, Sung B . NF-κB in cancer: a matter of life and death[J]. Cancer Discov, 2011,1(6):469-471.
|
[18] |
Liang J, Zhang ZQ, Liang LZ , et al. HIF-1α regulated tongue squamous cell carcinoma cell growth via regulating VEGF expression in a xenograft model[J]. Ann Transl Med, 2014,2(9):92.
|
[19] |
Joseph JP, Harishankar MK, Pillai AA , et al. Hypoxia induced EMT: a review on the mechanism of tumor progression and metastasis in OSCC[J]. Oral Oncol, 2018,80:23-32.
|
[20] |
张静, 滕宇, 赵晓婷 , 等. Wnt蛋白生成抑制剂2对非小细胞肺癌细胞迁移与侵袭能力的影响[J]. 癌变·畸变·突变, 2017,29(4):245-250.
|
|
Zhang J, Teng Y, Zhao XT , et al. Effects of the inhibitor of Wnt production 2 on cell migration and invasion in non-small cell lung cancer[J]. Carcinog Teratog Mutagen, 2017,29(4):245-250.
|
[21] |
Molinolo AA, Amornphimoltham P, Squarize CH , et al. Dysregulated molecular networks in head and neck carcinogenesis[J]. Oral Oncol, 2009,45(4/5):324-334.
|
[22] |
Quintanilla M, Brown K, Ramsden M , et al. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis[J]. Nature, 1986,322(6074):78-80.
|
[23] |
Chin L, Tam A, Pomerantz J , et al. Essential role for oncogenic Ras in tumour maintenance[J]. Nature, 1999,400(6743):468-472.
|
[24] |
朱孟雪, 李琦, 宋晨成 , 等. PI3K-AKT及MEK-ERK通路介导的HRAS-siRNA抑制人舌鳞状细胞癌CAL-27细胞增殖、迁移和侵袭能力的研究[J]. 临床口腔医学杂志, 2018,34(12):720-724.
|
|
Zhu MX, Li Q, Song CC , et al. Experimental study on the inhibitory effect of HRAS gene mediated by PI3K-AKT and MEK-ERK pathway on the proliferation, migration and invasion of human tongue squamous cell carcinoma CAL-27 cells[J]. J Clin Stomatol, 2018,34(12):720-724.
|
[25] |
McDonald JS, Jones H, Pavelic ZP , et al. Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck[J]. J Oral Pathol Med, 1994,23(8):342-346.
|
[26] |
Kohl NE, Omer CA, Conner MW , et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice[J]. Nat Med, 1995,1(8):792-797.
|
[27] |
Liu M, Sjogren AK, Karlsson C , et al. Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer[J]. Proc Natl Acad Sci USA, 2010,107(14):6471-6476.
|
[28] |
Marín-Ramos NI, Ortega-Gutiérrez S, López-Rodríguez ML . Blocking Ras inhibition as an antitumor strategy[J]. Semin Cancer Biol, 2019,54:91-100.
|
[29] |
张广钊, 黄桂林, 王新 , 等. 核因子κB与口腔癌关系的研究进展[J]. 中华口腔医学杂志, 2015,50(12):762-764.
|
|
Zhang GZ, Huang GL, Wang X , et al. Research progress on the relationship between NF-κB and oral cancer[J]. Chin J Stomatol, 2015,50(12):762-764.
|
[30] |
Wang IK, Lin-Shiau SY, Lin JK . Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation[J]. Oncology, 2000,59(3):245-254.
|
[31] |
Takada Y, Khuri FR, Aggarwal BB . Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-κB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-κB-regulated gene expression and up-regulation of apoptosis[J]. J Biol Chem, 2004,279(25):26287-26299.
|
[32] |
Yan M, Xu Q, Zhang P , et al. Correlation of NF-kappaB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma[J]. BMC Cancer, 2010,10:437.
|
[33] |
de Andrade Santos PP, de Aquino AR, Oliveira Barreto A , et al. Immunohistochemical expression of nuclear factor κB, matrix metalloproteinase 9, and endoglin (CD105) in odontogenic keratocysts, dentigerous cysts, and radicular cysts[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011,112(4):476-483.
|
[34] |
Arun P, Brown MS, Ehsanian R , et al. Nuclear NF-κB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer[J]. Clin Cancer Res, 2009,15(19):5974-5984.
|
[35] |
Jiang X, Takahashi N, Matsui N , et al. The NF-κB activation in lymphotoxin β receptor signaling depends on the phosphorylation of p65 at serine 536[J]. J Biol Chem, 2003,278(2):919-926.
|
[36] |
Han JY, Oh SH, Morgillo F , et al. Hypoxia-inducible factor 1α and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer[J]. J Natl Cancer Inst, 2005,97(17):1272-1286.
|